Scholar Rock Holding Corp SRRK
Free cash flow down to -$300.6M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (30, from the latest 10-K and 10-Q)
- EPS (ttm)
- -3.23
- Sales (ttm)
- 570K
- Net income (ttm)
- -413.6M
- Sales growth
- -
- EPS growth
- -
- Sales Q/Q
- -
- Free cash flow
- -309.9M
- Gross margin
- -
- Oper. margin
- n/m
- Net margin
- n/m
- FCF margin
- n/m
- ROE
- n/m
- ROA
- -92.7%
- R&D / sales
- -
- Dividend
- -
- Debt/Eq
- 1.16
- Curr. ratio
- 5.41
- Cash
- 366.3M
- Op. cash flow (ttm)
- -309.7M
- EBITDA
- -383.0M
- Net debt
- -170.1M
- Quick ratio
- 5.41
- Interest cover
- -55.80
- FCF after stock pay
- -376.2M
- Shares out.
- 122.0M
- Shares Y/Y
- +14.9%
- Book / share
- 1.38
- Cash / share
- 3.00
- Sales / share
- 0.00
- Asset turnover
- 0.00
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2018 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $245.5M
- = Tangible book value $245.5M
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
SRRK against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding Corp | $570K | - | - | - | - | - | 1.16 |
| OCUL Ocular Therapeutix, Inc | $50.4M | -18.5% | 87.3% | -648.6% | -74.1% | -530.0% | 0.17 |
| ROIV Roivant Sciences Ltd. | $41.1M | -71.6% | - | -838.2% | -8.6% | -81.2% | - |
| IDYA IDEAYA Biosciences, Inc. | $36.5M | - | - | - | -38.5% | -957.4% | - |
| CRSP CRISPR Therapeutics AG | $25.2M | -90.6% | - | - | -27.7% | - | 0.36 |
| CGON CG Oncology, Inc. | $6.2M | +255% | - | - | -24.0% | - | 0.00 |
Profitability
-
Net margin below the peer median-72563.2% vs 6.8%
-
Return on equity below 15%-245.2%
-
A profit in 0 of 6 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -55.8× interest expense
-
Debt larger than equityDebt / equity 1.16 on the latest balance sheet (peer median 0.69)
-
Current assets cover current liabilitiesCurrent ratio 5.41
-
More cash than debtNet cash $214.1M
Cash and shareholders
-
Free cash flow positive in 1 of 6 years−$300.6M last year
-
Share count up over 3 years+86.6%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
SRRK's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 20.5M | 15.4M | 18.8M | 33.2M | - | - | 0 |
| R&D | 19.9M | 36.3M | 54.2M | 74.1M | 108.5M | 124.4M | 121.9M | 184.6M | 208.4M |
| SG&A | 5.1M | 14.4M | 20.8M | 28.2M | 40.3M | 43.1M | 49.4M | 67.5M | 176.2M |
| Operating income | -25.0M | -50.7M | -54.5M | -86.9M | -129.9M | -134.4M | -171.3M | -252.1M | -384.6M |
| Interest expense | 53K | 34K | 27K | 400K | 2.1M | 4.7M | 6.5M | 6.8M | 6.9M |
| Pretax income | - | - | - | - | - | - | - | -246.3M | -377.7M |
| Net income | -25.0M | -49.3M | -51.0M | -86.5M | -131.8M | -134.5M | -165.8M | -246.3M | -377.9M |
| EPS (diluted) | -15.30 | -3.15 | -1.85 | -2.81 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 |
| Diluted shares | - | - | - | 30.7M | 36.7M | 59.6M | 83.3M | 99.8M | 114.7M |
| Depreciation & amortization | 669K | 807K | 1.3M | 1.5M | 2.6M | 3.0M | 2.8M | 1.9M | 1.7M |
| EBITDA | -24.4M | -49.9M | -53.2M | -85.4M | -127.3M | -131.4M | -168.5M | -250.1M | -383.0M |
| Operating margin | - | - | -266.2% | -564.0% | -690.5% | -404.8% | - | - | - |
| Net margin | - | - | -248.9% | -561.5% | -700.5% | -405.2% | - | - | - |
| Revenue growth | - | - | - | -24.8% | +22.2% | +76.4% | - | - | - |
Balance sheet
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash | 56.5M | 115.1M | 36.3M | 160.4M | 212.8M | 103.3M | 101.9M | 177.9M | 323.5M |
| Short-term investments | 1.5M | 60.6M | 121.1M | 180.7M | 40.2M | 212.1M | 178.1M | 259.4M | 44.0M |
| Receivables | - | - | 25.0M | - | - | - | - | - | 0 |
| Inventory | - | - | - | - | - | - | - | - | 0 |
| Current assets | 59.2M | 177.9M | 185.2M | 344.4M | 265.3M | 328.0M | 288.2M | 451.2M | 385.1M |
| Property & equipment | 2.2M | 3.2M | 4.2M | 8.1M | 9.6M | 7.4M | 4.6M | 2.8M | 1.7M |
| Total assets | 61.6M | 181.3M | 196.4M | 388.3M | 304.4M | 358.2M | 311.0M | 474.9M | 404.3M |
| Accounts payable | 1.4M | 3.3M | 1.1M | 3.4M | 4.4M | 4.0M | 3.5M | 10.1M | 10.3M |
| Current liabilities | 5.0M | 31.1M | 32.8M | 42.6M | 64.3M | 36.4M | 32.7M | 46.9M | 55.4M |
| Total debt | 398K | 462K | - | 26.0M | 53.6M | 51.0M | 52.3M | 50.1M | 99.7M |
| Total liabilities | 5.9M | 74.7M | 83.5M | 127.5M | 132.4M | 97.9M | 85.8M | 106.3M | 158.8M |
| Shareholders' equity | -53.5M | 106.6M | 112.9M | 260.8M | 172.1M | 260.2M | 225.2M | 368.6M | 245.5M |
| Retained earnings | -57.5M | -106.8M | -157.8M | -244.3M | -376.1M | -510.6M | -676.4M | -922.7M | -1.3B |
Cash flow
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.7M | 24.6M | -63.1M | -60.3M | -126.8M | -132.7M | -145.2M | -200.9M | -300.0M |
| Capital spending | 361K | 1.5M | 3.1M | 4.1M | 5.2M | 1.1M | 71K | 98K | 602K |
| Free cash flow | -22.1M | 23.1M | -66.2M | -64.4M | -132.0M | -133.8M | -145.3M | -201.0M | -300.6M |
| Stock-based pay (added back) | 1.5M | 5.2M | 8.0M | 11.2M | 23.1M | 27.7M | 27.1M | 36.6M | 75.6M |
| Free cash flow after stock pay | -23.6M | 17.9M | -74.2M | -75.5M | -155.2M | -161.5M | -172.4M | -237.7M | -376.2M |
| Debt raised | - | - | - | 24.6M | 25.0M | - | - | - | 24.7M |
| Debt repaid | - | 667K | 365K | - | - | - | - | - | 25.5M |
| Investing cash flow | 17.7M | -60.2M | -62.2M | -63.5M | 134.3M | -171.7M | 41.1M | -76.1M | 218.7M |
| Financing cash flow | 50.5M | 94.3M | 48.9M | 247.8M | 45.0M | 194.8M | 102.6M | 353.0M | 228.4M |
Stock-based pay and leases
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 1.5M | 5.2M | 8.0M | 11.2M | 23.1M | 27.7M | 27.1M | 36.6M | 75.6M |
| Stock-based pay / revenue | - | - | 38.9% | 72.6% | 123.0% | 83.5% | - | - | - |
| Operating lease cost | - | - | 1.4M | 3.2M | 8.6M | 8.7M | 8.3M | 7.0M | 6.9M |
| Operating lease cash paid | - | - | 1.3M | 2.1M | 8.9M | 9.2M | 9.1M | 8.1M | 7.4M |
| Right-of-use assets | - | - | 4.4M | 32.3M | 25.4M | 18.5M | 11.4M | 15.6M | 10.4M |
| Operating lease liabilities | - | - | 5.3M | 32.5M | 27.1M | 19.7M | 11.8M | 15.0M | 9.2M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.